Skip to content

Isomorphic Labs Lands $5B in Largest-Ever UK AI Startup Round—What It Means for Drug Disco

·StartupReader editorial desk· 2 min readReviewed by our editors

Sir Demis Hassabis has raised $5 billion for Isomorphic Labs, the largest investment ever in a British AI startup and a milestone for the intersection of artificial intelligence and drug development. The funding, led by Greenoaks Capital and including Sequoia Capital and Andreessen Horowitz, values the London-based company at $50 billion, positioning it as Britain’s most valuable AI venture.

The round comes as Isomorphic, founded in 2021 as a spinout from Hassabis’s former company DeepMind, shifts toward clinical trials. The company has already secured partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with potential billions in future payments if its AI-designed drug candidates succeed.

Hassabis, who won a Nobel Prize in chemistry in 2024 for AI-driven protein research, described the $5 billion as critical to advancing "foundational biology models" and accelerating therapeutic programs. The funding will also support collaborations with pharmaceutical giants, though Isomorphic has yet to produce a trial-ready drug.

The round’s timing is notable. Just weeks earlier, Sequoia announced it would shut its London office, citing no need for a local presence. Yet the firm’s participation in Isomorphic’s funding suggests continued confidence in the UK’s AI ecosystem, even amid broader investor consolidation. The UK Government’s Sovereign AI Fund, a taxpayer-backed initiative, also contributed, reflecting both political and economic interest in the company’s success.

Isomorphic’s ambitions extend beyond drug discovery. The company has framed its approach as "advanced reasoning" applied to molecular design, a shift from earlier AI-driven efforts that relied on brute-force computational screening. According to Hassabis’s remarks, the $5 billion will enable "unprecedented precision and speed" in generating drug candidates—claims that will face scrutiny as the company moves toward clinical trials.

The funding also highlights a broader trend: AI’s role in pharma is evolving from research assistance to a core driver of therapeutic innovation. Competitors like Pathos AI (which raised $237 million in September) and ALLOX (a $10.5 million seed round in October) are scaling similarly, but none have matched Isomorphic’s valuation or investor backing. The company’s partnerships with major pharma firms suggest it may set the standard for AI-driven drug development, even as skepticism persists about translating computational models into viable treatments.

What to watch: Whether Isomorphic’s AI-generated molecules translate into clinical success—and whether its valuation holds as it progresses beyond pre-clinical stages. The company’s ability to execute will determine whether this round marks the beginning of a new era in drug discovery or a high-stakes gamble on unproven technology.

Sources: finance.yahoo.com

“This funding round signals a new phase for AI-driven drug discovery, where scale and ambition outpace even the most optimistic projections.”
— StartupReader
ShareLinkedInXWhatsApp

One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.

Read the original reporting

The outlets below did the original reporting.

Related briefs

This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.